Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nanotech Report’s Recommendations Unsettling To Supplement Industry

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement industry groups say an FDA panel's report citing the lack of information about working with nanotechnology should prompt the agency to be cautious about acting on the panel's recommendation to issue a guidance on using nano-materials in new dietary ingredients

Related Content

FDA Nanotech Guidance Takes Small Step Forward
FDA Considers Guidance For Nano-Engineered Supplements
Lawyers Urge Firms To Be Ready For Nanotech Torts, Tougher Inspections
Defining Nanotech Included In Working Group’s 10-Point Standardization Goal
Consumer Groups Uneasy, FDA Cautious Over Nanotech In Supplements
Nanomaterials public meeting
FDA Eyes Nanotech Standards Process With More Unknown Than Known
International Forum Seeks Data To Harmonize Personal Care Product Labeling
Nanotech Researchers Say Federal Agenda “Like A Ship Without A Captain”
Nanotech Regulation Issue Clouded By Friends Of The Earth Sunscreen Guide





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts